DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
20.74
-0.08 (-0.38%)
Nov 18, 2026, 2:55 PM CST
SHA:603233 Revenue
DaShenLin Pharmaceutical Group had revenue of 7.32B CNY in the quarter ending September 30, 2026, with 11.78% growth. This brings the company's total for the last twelve months to 28.74B, up 7.11% year-over-year. In the year 2025, DaShenLin Pharmaceutical Group had annual revenue of 27.50B with 3.80% growth. That makes DaShenLin Pharmaceutical Group the 2,940th largest company in the world by revenue and 342nd in China.
Revenue (ttm)
28.74B
Revenue Growth
+7.11%
P/S Ratio
0.82
Revenue / Employee
698.62K
Employees
41,141
Market Cap
23.62B
Revenue by Segment
- Retail 22.35B 81.4%
- Franchise and Distribution 4.48B 16.3%
- Other Operations 635.01M 2.3%
Fiscal year ended Dec 31, 2025 See the full SHA:603233 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.50B | 1.01B | 3.80% |
| Dec 31, 2024 | 26.50B | 1.97B | 8.01% |
| Dec 31, 2023 | 24.53B | 3.28B | 15.45% |
| Dec 31, 2022 | 21.25B | 4.49B | 26.78% |
| Dec 31, 2021 | 16.76B | 2.18B | 14.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yifeng Pharmacy Chain | 25.38B |
| LBX Pharmacy Chain Joint Stock Company | 22.82B |
| Luyan Pharma | 21.57B |
| Cachet Pharmaceutical | 17.25B |
| Yixintang Pharmaceutical Group | 17.03B |
| ShuYu Civilian Pharmacy Corp. | 10.85B |
| Jianzhijia Pharmaceutical Chain Group | 8.65B |
| Anhui Huaren Health Pharmaceutical | 5.91B |